New drugs approved for marketing after clinical trials (China registration category)
RecordSTO-V2JYK200N2-K5Z3HSF7J6-60P114
China · 2025
New drugs approved for marketing after clinical trials in China (China registration category) was 248 in 2025 (NHSA).
- Publisher
- NHSA
- Authority tier
- T1 Official
- Locator
- 试验包括新药临床试验和生物等效性试验
- Retrieved
- 17 Sep 2026
- Status
- Verified
What the source says
国家药监局药审中心副主任杨志敏则表示，2025年，我国共有248个新药通过临床试验获批上市，涵盖了抗肿瘤、内分泌、精神障碍等18个适应症领域。
Checked: the figure 248 is stated in this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
APA
National Healthcare Security Administration. (2025). 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_V2JYK200N2K5Z3HSF7J660P114
Other formats: MLA, Chicago, BibTeX
- MLA
- National Healthcare Security Administration. "从“0”到“1”创新能力增强 我国新药研发热度持续攀升." 2025, http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_V2JYK200N2K5Z3HSF7J660P114.
- Chicago
- National Healthcare Security Administration. "从“0”到“1”创新能力增强 我国新药研发热度持续攀升." 2025. http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_V2JYK200N2K5Z3HSF7J660P114.
- BibTeX
- @misc{nhsa2025drugs60p114, author = {{National Healthcare Security Administration}}, title = {从“0”到“1”创新能力增强 我国新药研发热度持续攀升}, year = {2025}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_V2JYK200N2K5Z3HSF7J660P114}, note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\_14\_21076.html. Accessed September 17, 2026.} }
Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Primary source
- Publisher
- National Healthcare Security Administration · homepage ↗
- Authority tier
- Tier 1 · Multilateral Official
- Report
- 从“0”到“1”创新能力增强 我国新药研发热度持续攀升
- Type
- Press release
- Published
- —
- Locator
- 试验包括新药临床试验和生物等效性试验
- Retrieved
- 17 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification
- Status
- Verified
- Review protocol
- editorial:evidence-check-v1:2026-09-26
- Checked on
- 26 September 2026
- Last revision
- 26 September 2026
- Permanent URL
- /stat/stat_V2JYK200N2K5Z3HSF7J660P114